… inhibitor), S63845 (an MCL-1-selective inhibitor), ABT263 (a dual BCL-X L and BCL-2
inhibitor), and DT2216 (a BCL-X L specific PROTAC or degrader) as single agents as well as in …

… ) over other STAT isoforms 61 and for BCL-XL over BCL-2 (ref. ) even … ARD-69, a VHL-recruiting
PROTAC, achieved complete … ARD-61 is the most potent AR PROTAC degrader to date, …

… that they are not very potent or effective in degrading either SMARCA2 or SMARCA4 protein…
selectivity could be achieved for SMARCA2 over SMARCA4 by PROTAC degraders using a …

… Compared to other cancers, the MCL-1:BCL-xL mRNA and … manner and show potent
anti-tumor activity in preclinical cancer … The second PROTAC combined another MCL-1 binding …

… The resulting PROTAC DT2216 effectively degraded BCL-XL in T-cell acute … in the PROTAC
XZ739 effectively degrading BCL-XL and demonstrating good antiproliferative activity in T-…

… and XL01126 degraded LRRK2 at higher rates and achieved … With a potent, fast, and selective
LRRK2 degrader in hand, … that report on LRRK2 activity. Mitochondrial dysfunction is one …

… –PROTAC–E3 ligase ternary complex triggers ubiquitin transfer from E2 to the target protein.
The polyubiquitin-labeled POI is then degraded via the proteasome, and the PROTAC is …

… Results of this research indicated that the ability of a unique PROTAC to degrade target …
PROTAC-4C can be achieved by ultraviolet irradiation. Among them, the trans-4C could degrade …

… (PROTAC) that can selectively degrade BCL-XL via the VHL ubiquitin E3 ligase (20). Our lead
BCL-XL PROTAC, … Second, this particular PROTAC was effective at engaging BCL-XL but …

… Having identified dNCL#T1 as a potent NCL degrader, we thus examined its antitumor
efficacy in cancer cells. The expression levels of NCL were elevated in the examined cancer cell …